Enquire

News archive

2025

Domainex Appoints Hayley French as Chief Executive Officer

2024

Nuclera’s eProtein Discovery system installed at Domainex to streamline protein production services

Domainex included in inaugural special report from the Financial Times recognising Europe’s Long-Term Growth Champions

HM Lord-Lieutenant of Cambridgeshire Opens Domainex’s New Biology Centre of Excellence and Presents the King’s Award for Enterprise

2023

Domainex expands biophysical capabilities with the purchase of new equipment from Malvern Panalytical

Domainex expands its research operations by securing from Howard Group a new facility at Unity Campus

Domainex secures a prestigious King’s Award for Enterprise

2022

Domainex expands Executive and Management Teams to support ongoing growth

Amphista Therapeutics partners with Domainex to advance portfolio of drug discovery projects targeting protein degradation

Anti-inflammatory drug candidate DMXD-011 shows efficacy in ex-vivo human studies

Domainex appoints Eddy Littler as Executive Chairman

NRG Therapeutics Selects Domainex to be its Integrated Drug Discovery Partner for its Biomedical Catalyst Funded Parkinson’s Disease Project

Domainex appoints Dr Scott Martin as Analytical and Bioanalytical Group Leader

Domainex expands analytical chemistry capabilities with over £1M worth of new Waters equipment

Domainex opens a dedicated new facility at Unity Campus to expand research operations

Parkinson’s UK and Domainex collaborate to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s

Queen’s University Belfast enters collaboration and licensing agreement with Ipsen to progress FLIP inhibitor project which has been supported by Domainex

2021

Domainex wins Best CRO at OBN Awards

Domainex expands executive team to support ongoing growth

Domainex invests in the Creoptix WAVEdelta to strengthen its fragment-based drug discovery platform

2020

APEIRON Biologics AG and Domainex Ltd announce the expansion of their partnership to progress targeted cancer immune therapy drug discovery

Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemia.

Domainex announces the appointment of Dr. Eddy Littler as non-executive Chairman

LUNAC Therapeutics selects Domainex as its strategic drug discovery partner

Domainex announces the appointment of Tom Mander as Chief Executive Officer

2019

Novel first-in-class FLIP inhibitors for the treatment of cancer

Potential new treatment for heart attack: Prospective drug found by testing in human heart muscle grown from stem cells

2018

Domainex article featured on the front cover of Molecular Pharmacology

Domainex appoints Dr Trevor Perrior as Chief Executive Officer

Domainex ranked as the fastest growing drug discovery CRO in Europe

Domainex wins award to develop GPCR drug discovery technology

2017

Scientists Present Positive Progress in the Development of a New Class of Broad-spectrum Organogold Antibiotics

Domainex Signs Multi-Year Agreement with Dotmatics to Streamline Its Integrated Drug Discovery Services

2016

Domainex Invests in NanoTemper MicroScale Thermophoresis Technology to Advance its Fragment-based Drug Discovery Services

The New Domainex Medicines Research Centre is Opened by Sir Simon Campbell

Chesterford Research Park proves ideal new home for Domainex

Queen’s University Belfast and Domainex Win Late-Stage Award to Progress Novel Lung Cancer Drug Candidate into the Clinic

Johnson Matthey and Domainex Collaborate to Enhance Discovery and Development Services for UK Pharma, Biotech and Academia

University of Leicester scientist wins Domainex’s STAR Award to support her search for a treatment for non-Hodgkin lymphomas

Domainex and Cresset Announce Drug Discovery Services Alliance

2015

Controlling the ‘Social Life’ of Proteins Aims to Transform Drug Discovery

Domainex Announces Expansion of Its Service Business with a Move to New Research Building with Larger Facilities

Domainex and Imperial College London Partner to Discover New Therapies to Treat Myocardial Infarction

Auspherix and Domainex Expand Collaboration to Develop New Drugs that Tackle Antibiotic-Resistant Bacterial Infections

Domainex prepares for expansion as it announces the appointment of Barry Knight as Chief Financial Officer and Company Secretary, and Thomas Mander as Chief Operating Officer.

Domainex Launches New BioassayBuilder Service to Strengthen its Drug Discovery Platform

Domainex announces the grant of US and European patents for its lead programme, targeting IKK epsilon and TBK1 for the Treatment of diseases such as COPD and Psoriasis.

Queen’s University Belfast and Domainex in Cutting-Edge Collaboration to Advance Novel Lung Cancer Drug Research

2014

Press Release – ZoBio and Domainex Join Forces to Deliver Crucial Drug Target Information to support FORMA Therapeutics’ Drug Discovery Programs

Auspherix and Domainex Announce Collaboration to Develop New Drugs to Treat Antibiotic-resistant Bacterial Infection

Domainex Reports Success of its Lead Compound in Pre-clinical Model of COPD and Secures £1.4m Biomedical Catalyst Award

2013

Domainex CSO, Prof Laurence Pearl, wins prestigious CRUK Translational Research Award

University of Warwick wins Domainex’s first Discovery STAR Award to Support hunt for new Chagas Disease Treatment

Domainex Launches Discovery STAR Award to Support Early Academic Drug Discovery

2010

Domainex and Pharmidex announce drug discovery services alliance

Start your next project with Domainex

Contact one of our experts today